V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210031474 | 210013658 | 1.53 | 60.4 | Palliative (P) | null | 2016-09-02 | DACTINOMYCIN + CYCLO + VINCRISTINE | 2 | N | 210042069 | PACLITAXEL |
| 210031475 | 210022533 | 1.57 | 66 | Palliative (P) | 2017-07-15 | 2017-07-16 | Cyclophosphamide High Dose | 02 | N | 210042072 | ICE |
| 210031476 | 210013662 | 1.67 | 64.6 | null | 2018-04-23 | 2018-05-02 | Capecitabine (14 day) + Irinotecan | N | N | 210042107 | IDARUBICIN + MERCAPTOPURINE + METHOTREXATE + VINCRISTINE |
| 210031477 | 210013663 | 1.77 | 73.9 | Curative (C) | 2016-04-20 | 2016-08-02 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE | Y | N | 210042133 | BR14 TRIAL |
| 210031478 | 210013666 | 1.65 | null | null | null | 2018-02-15 | Ofatumumab Weekly | N | null | 210042147 | PACKER MAINTENANCE |
| 210031479 | 210013672 | null | 0 | Curative (C) | 2017-01-13 | 2017-01-21 | Cytarabine Intrathecal (any age) | null | null | 210042169 | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE |
| 210031480 | 210013673 | null | 52.6 | Curative (C) | 2017-12-27 | 2018-09-19 | RCEOP | null | null | 210000284 | BEVACIZUMAB + NIVOLUMAB |
| 210031481 | 210013676 | 1.75 | 7.1 | Curative (C) | 2017-02-05 | 2018-09-25 | TRASTUZUMAB | N | N | 210001193 | BEVACIZUMAB + NIVOLUMAB |
| 210031482 | 210013678 | 1.73 | 68.5 | Disease modification (D) | 2017-08-02 | 2017-11-25 | TRASTUZUMAB | N | null | 210001293 | IRINOTECAN + TEMOZOLOMIDE |
| 210031483 | 210013679 | 1.9 | 69.8 | Disease modification (D) | null | 2019-06-02 | Bortezomib + CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB | 02 | N | 210004103 | IDARUBICIN + MERCAPTOPURINE + METHOTREXATE + VINCRISTINE |
| 210031484 | 210013684 | 1.68 | 32.5 | Disease modification (D) | 2019-05-30 | 2019-05-30 | Bevacizumab + Irinotecan | N | N | 210008519 | CARBOPLATIN + PROCARBAZINE |
| 210031485 | 210013685 | null | 102 | Disease modification (D) | 2017-05-16 | 2017-05-17 | Cytarabine intrathecal | N | N | 210008669 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210031486 | 210013687 | 1.76 | 92.4 | Palliative (P) | 2018-01-28 | 2018-02-13 | Cyclophosphamide High Dose | 2 | null | 210008796 | RCEOP |
| 210031487 | 210013691 | 1.57 | 0 | Adjuvant (A) | 2017-07-21 | 2017-09-29 | PACLITAXEL | Y | N | 210010386 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210031488 | 210013693 | 1.82 | 82.1 | Curative (C) | 2015-04-08 | 2017-11-02 | CLL210 TRIAL | 2 | N | 210011848 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210031489 | 210013696 | null | null | null | 2019-03-04 | 2019-03-26 | IDARUBICIN | 99 | Y | 210012655 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210031490 | 210013698 | 1.62 | null | Palliative (P) | 2017-03-12 | 2017-03-14 | Fludarabine IV | Y | N | 210014040 | MYELOMA XI TRIAL |
| 210031491 | 210028153 | 1.75 | null | null | 2019-01-07 | 2019-02-10 | Paclitaxel (2 or 3 weekly) | 02 | N | 210014521 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210031492 | 210013702 | null | 117.5 | Palliative (P) | null | 2018-07-28 | Maintenance Therapy ALL | Y | N | 210018519 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE |
| 210031493 | 210013707 | 1.83 | 66.8 | Palliative (P) | 2019-08-29 | 2019-09-19 | CYTARABINE + FLUDARABINE + IDARUBICIN | 02 | Y | 210021249 | DAUNORUBICIN + VNCRISTINE |
| 210031494 | 210022562 | 1.65 | 73.55 | Palliative (P) | 2018-03-15 | 2018-11-25 | CETUXIMAB + IRINOTECAN | Y | N | 210021270 | ALL MAINTENANCE |
| 210031495 | 210013709 | 1.78 | 96.1 | Curative (C) | 2018-07-29 | 2018-08-04 | CNS Medbl Std Risk Maint Cisplatin | N | null | 210021324 | CYTARABINE + RITUXIMAB |
| 210031496 | 210013712 | 1.83 | null | null | 2018-11-14 | 2018-11-14 | Bevacizumab + Irinotecan | N | N | 210021726 | FLAG |
| 210031497 | 210013713 | null | 54 | null | 2018-02-17 | 2018-02-18 | Hydroxycarbamide | null | null | 210021743 | FLUDARABINE |
| 210031498 | 210013718 | 1.54 | 54.4 | Palliative (P) | 2017-07-31 | 2017-07-31 | IVE-R | 02 | N | 210021911 | ALL MAINTENANCE |
| 210031499 | 210013720 | null | 58.4 | Palliative (P) | 2013-11-18 | 2016-05-06 | Azacitidine | N | N | 210022095 | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE |
| 210031500 | 210013723 | 1.79 | 68.6 | Curative (C) | 2019-01-31 | 2019-02-07 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | 2 | N | 210022560 | UKALL2003 |
| 210031501 | 210013725 | 1.7 | 70.2 | Palliative (P) | 2015-10-23 | 2015-11-12 | Alemtuzumab + Cyclophos TBI Allo | 2 | N | 210022634 | CLARITY TRIAL |
| 210031502 | 210013730 | 0 | 75.2 | Palliative (P) | 2017-05-18 | 2017-05-31 | CARBOPLATIN + LOMUSTINE + VINCRISTINE | N | N | 210023716 | CYTARABINE + ETOPOSIDE |
| 210031503 | 210022581 | 0 | null | Curative (C) | 2015-08-26 | 2015-09-23 | ICE-R | 2 | N | 210024647 | DARATUMUMAB |
| 210031504 | 210013745 | 1.56 | 82 | Palliative (P) | 2019-06-17 | 2019-07-03 | BR14 TRIAL | N | N | 210024837 | ALL MAINTENANCE |
| 210031505 | 210022584 | null | 61 | null | null | 2018-09-12 | Alemtuzumab+Busulfan+CyclophosphMUD | null | null | 210025000 | ICE-R |
| 210031506 | 210013747 | 0 | null | 5 | 2017-10-27 | 2017-11-07 | BR14 TRIAL | N | N | 210025077 | CYTARABINE |
| 210031507 | 210013750 | null | 74 | Palliative (P) | 2016-09-20 | 2016-10-04 | DARATUMUMAB | 02 | N | 210025389 | IDARUBICIN + MERCAPTOPURINE + METHOTREXATE + VINCRISTINE |
| 210031508 | 210022590 | 1.64 | 87.4 | Curative (C) | 2016-12-19 | 2017-04-13 | Oxaliplatin + Modified de Gramont | 2 | null | 210025657 | CLL210 TRIAL |
| 210031509 | 210013757 | 1.72 | 91.2 | Curative (C) | 2018-11-14 | 2019-01-15 | TRASTUZUMAB | N | N | 210025797 | ALL INDUCTION |
| 210031510 | 210028173 | 0 | 16.2 | Disease modification (D) | 2017-05-02 | 2017-05-28 | ALEMTUZUMAB + ETOPOSIDE | 02 | N | 210025907 | MYELOMA XI TRIAL |
| 210031511 | 210033700 | null | 86.4 | Disease modification (D) | null | 2017-01-08 | IMMUNOGLOBULIN | null | null | 210025962 | ALEMTUZUMAB + ETOPOSIDE |
| 210031512 | 210033701 | 1.78 | 60.8 | Curative (C) | 2018-02-10 | 2018-05-08 | Cyclophosphamide High Dose | N | N | 210026674 | ALL |
| 210031513 | 210013763 | 1.57 | 64.1 | Neo-adjuvant (N) | 2013-12-28 | 2014-03-18 | DOXORUBICIN | N | N | 210026763 | RUXOLITINIB |
| 210031514 | 210013767 | 1.73 | 12.7 | Curative (C) | 2018-03-17 | 2018-03-18 | Brentuximab | null | null | 210027544 | PACLITAXEL |
| 210031515 | 210013768 | 1.83 | 16.3 | null | 2015-01-28 | 2016-03-14 | Depocyte Intrathecal | N | null | 210027549 | ICE |
| 210031516 | 210013769 | 1.63 | 61.8 | Curative (C) | 2014-07-23 | 2014-09-09 | Intensification 1 2 3(ALL) (Mtx) | 1 | N | 210027566 | CLARITY TRIAL |
| 210031517 | 210013773 | 0 | 86.4 | Disease modification (D) | 2019-04-04 | 2019-04-04 | BR14 TRIAL | N | N | 210027899 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 210031518 | 210013781 | 1.6 | 57 | Curative (C) | 2019-05-14 | 2019-05-19 | Cytarabine HD + Methotrexate HD | N | N | 210028000 | R-EPOCH |
| 210031519 | 210013781 | null | 70.4 | Palliative (P) | null | 2014-10-23 | Azacitidine | Y | null | 210028000 | CYTARABINE INTRATHECAL |
| 210031520 | 210013785 | 1.6 | 60.6 | Curative (C) | 2017-10-04 | 2017-12-12 | PACLITAXEL | N | null | 210028634 | CVD |
| 210031521 | 210031567 | null | 60.4 | Curative (C) | 2019-02-25 | 2019-06-11 | Alemtuzumab+Busulfan+CyclophosphMUD | N | N | 210029239 | RCEOP |
| 210031522 | 210022615 | 1.54 | 82.3 | Curative (C) | 2019-03-01 | 2019-04-05 | Cladribine + Rituximab | 2 | N | 210029261 | IVAC |
| 210031523 | 210013802 | 1.77 | 98 | Disease modification (D) | 2016-08-07 | 2017-02-11 | CVAD | 02 | N | 210029535 | CYCLOPHOSPHAMIDE HIGH DOSE |